Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 364

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 364
---
 on the accompanying statements of operations.

The CODM uses the information primarily to evaluate the
Company’s performance and allocate resources. This includes reviewing key financial metrics such as budget versus actual expenditures and assessing overall cash flow and liquidity to ensure the continuity of operations. This approach allows
the CODM to monitor the Company’s performance and make strategic adjustments as needed to support its operational and financial goals.

The
Company’s operations and all long-lived assets are located in the United States.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash and cash
equivalents primarily consist of balances held at one financial institution and in money market funds. Cash balances may, at times, exceed the Federal Deposit Insurance Corporation (“FDIC”) amounts. Management periodically assesses the
financial condition of the banking institution and believes that any potential credit loss is minimal. As of December 31, 2024 and 2023, the Company’s cash balance exceeded the FDIC insured limit of $250,000.

Restricted Cash

Restricted cash primarily
consists of certificates of deposit that are held as collateral against the letter of credit that the Company is required to maintain for its operating lease agreement.

F-9

LB Pharmaceuticals Inc Notes to Financial Statements Marketable Securities The Company accounts for marketable securities held as “available-for-sale”in accordance with Accounting Standards Codification (“ASC”) 320, Investments-Debt Securities.The Company classifies these investments as current assets and carries them at fair value. Unrealized gains and losses are recorded as a separate component of stockholders’ deficit as accumulated other comprehensive income. Realized gains or losses on marketable security transactions are reported in the statements of operations. Marketable securities are maintained at one financial institution and are governed by the Company’s investment policy, as approved by the Company’s board of directors. The Company evaluates its marketable securities with unrealized loss positions for impairment by assessing if they are related to deterioration in credit risk and whether the entire amortized cost basis of the security will be recovered, the intent to sell, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their cost basis. Credit-related impairment losses, not to exceed the amount that fair value is less than the amortized cost basis, are recognized through an allowance for credit losses with changes in the allowance for credit losses recorded in the statements of operations. No impairment losses related to marketable securities have been